NTRA
Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$325.55
−0.65%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−257.2x
Market Cap
$46.93B
MomentumView details →
1D Return
−0.65%
YTD Return
+41.86%
RSI (14)
60.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−257.2x
Market Cap
$46.93B
RSI (14)
60.4
MomentumView details →
1D Return
−0.65%
YTD Return
+41.86%
SummaryUpdated Jun 1, 2026
Natera, Inc. (NASDAQ:NTRA) is a molecular diagnostics company founded in 2003 and headquartered in Austin, Texas. Originally known as Gene Security Network, Inc., the company changed its name to Natera in 2012 and went public in 2015. Natera has evolved from a genetics-focused startup into a leading provider of genetic testing services across three primary healthcare segments: women's health, oncology, and organ health. The company develops and commercializes advanced molecular testing services that analyze DNA to provide critical medical information for patients and healthcare providers worldwide.
Similar companies
Latest newsMore news →
Natera announced a national partnership with Susan G. Komen to accelerate breast cancer awareness and education, including efforts to increase understanding of minimal residual disease (MRD).7d agoNatera announced a collaboration with Angiex to use its Signatera test to assess response to Angiex's investigational antibody-drug conjugate AGX101 in a Phase I clinical trial.8d agoCallan Family Office LLC acquired a new position in Natera, Inc. by purchasing 3,582 shares valued at approximately $972,000 during the second quarter, as disclosed in a recent SEC filing.10d ago